Ferrufino, C. P., Munakata, J., Wei, W., Proudfoot, C., Kuznik, A., Boklage, S. H., & Chen, C. (2018). Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. Clinicoecon Outcomes Res.

Ferrufino, Cheryl P., Julie Munakata, Wenhui Wei, Clare Proudfoot, Andreas Kuznik, Susan H. Boklage, et Chieh-I Chen. "Budget Impact Analysis of Sarilumab for the Treatment of Rheumatoid Arthritis in Patients With an Inadequate Response to Conventional Synthetic DMARD or TNF Inhibitor Therapies." Clinicoecon Outcomes Res 2018.

Ferrufino, Cheryl P., et al. "Budget Impact Analysis of Sarilumab for the Treatment of Rheumatoid Arthritis in Patients With an Inadequate Response to Conventional Synthetic DMARD or TNF Inhibitor Therapies." Clinicoecon Outcomes Res 2018.